Clinical Efficacy of Dapagliflozin in Heart Failure Patients with Reduced Ejection Ejection Fraction
CUI Liuyi
ZHAO Ziming
CHEN Yuan
CHEN Jian
Abstract：Objective To investigate the clinical evaluation of dapagliflozin in heart failure patients with reduced ejection fraction(HFrEF).Methods A total of 130 HFrEF patients with hypotension admitted to the Cardiology Department of Zhengzhou Cardiovascular Hospital from October 2021 to June 2022 were randomly divided into control group and observation group,with 65 cases in each group.The control group was treated with conventional drugs,and the observation group was treated with dapagliflozin in addition to conventional drugs.All patients were followed up for 12 months.The primary end point included the patient's hospitalization for recurrence of heart failure,cardiovascular death.The secondary endpoint included blood pressure,heart rate,6 minutes walking test distance,left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP).Adverse events(abnormal renal function,abnormal blood potassium level,hypovolemia,hypoglycemia)were also recorded during the 12 months treatment period in both groups.Results Twelve months after treatment,the patient's hospitalization for recurrence of heart failure and cardiovascular death in the observation group were lower than that in the control group(P＜0.05).Heart rate,LVEDD,NT-proBNP in observation group were lower and systolic blood pressure,6 minutes walking test distance,LVEF were higher than those in control group(P＜0.05).There was no significant difference in the adverse events between the two groups(P＞0.05).Multivariate Cox regression analysis showed that dapagliflozin use was an independent predictor of readmission rate for recurrence of heart failure(HR=0.551,95％CI:0.319-0.952,P=0.033)and cardiovascular mortality(HR=0.317,95％CI:0.153-0.656,P=0.002)in advanced heart failure patients with hypotension.Conclusion Dapagliflozin improves cardiac function in HFrEF patients with hypotension,reduces heart failure readmitted rates and cardiovascular mortality,and does not increase the risk of adverse events.
Keywords：heart failurereduced ejection fractiondapagliflozinhypotension
Publication Date：2025-01-14
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：5( 24-28 )